20. DEUTSCHER ALLERGIE KONGRESS

Auswirkungen von oralem Sebetralstat auf Angstzustände im Zusammenhang mit hereditären Angioödem-Attacken in der KONFIDENT Phase-3-Studie

Emel Aygören-Pürsün,[1] Jonathan A. Bernstein,[2] Timothy J. Craig,[3] Paula J. Busse,[4] Teresa Caballero,[5] Danny M. Cohn,[6] Mar Guilarte,[7] Henriette Farkas,[8] Douglas H. Jones,[9] Sorena Kiani-Alikhan,[10] Michael E. Manning,[11] Marcus Maurer,[12] Marc A. Riedl,[13] Sinisa Savic,[14] H. James Wedner,[15] Patrick F. K. Yong,[16] Andrea Zanichelli,[17,18] Erik Hansen,[19] James Hao,[19] Michael D. Smith,[19] Christopher M. Yea,[19] Paul K. Audhya,[19] William R. Lumry[20]

[1]University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany; [2]University of Cincinnati College of Medicine, and Bernstein Clinical Research Center, Cincinnati, OH, USA; [3]Departments of Medicine, Pediatrics, Ob/Gyn MFM, and Biomedical Sciences, Pennsylvania State University, Hershey, PA, USA; Vinmec International Hospital, Times City, Hanoi, Vietnam; [4]Department of Medicine, Icahn School of Medicine at Mount Sinai School of Medicine, New York, NY, USA; [5]Servicio de Alergia, Hospital La Paz Health Research Institute, Biomedical Research Network on Rare Diseases, Madrid, Spain; [6]Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands; [7]Department of Allergy, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain; [8]Hungarian Angioedema Center of Reference and Excellence, Semmelweis University, Budapest, Hungary; [9]Rocky Mountain Allergy, Asthma, and Immunology, Layton, UT, USA; [10]Division of Infection and Immunity, University College London, London, UK; [11]Medical Research of Arizona, Scottsdale, AZ, USA; and University of Arizona College of Medicine-Phoenix, Phoenix, AZ, USA; [12]Institute of Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universitätsmedizin Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany; [13]University of California, San Diego, La Jolla, CA, USA; [14]The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; [15]John T. Milliken Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA; [16]Department of Immunology, Frimley Health NHS Foundation Trust, Frimley, UK; [17]Operative Unit of Medicine, Angioedema Center, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy; [18]Department of Biomedical Science for Health, University of Milan, Milan, Italy; [19]KalVista Pharmaceuticals, Salisbury, UK, and Framingham, MA, USA; [20]AARA Research Center, Dallas, TX, USA

Disclosure: Emel Aygören-Pürsün has received grants, consulting fees, honoraria, fees paid to the institution, and/or personal fees from KalVista Pharmaceuticals, Astria, BioCryst, CSL Behring, Intellia, Otsuka, Pharvaris, and Takeda/Shire.

Background

- Many people living with HAE experience severe anxiety due to the unpredictability of attacks and use of injectable on-demand treatments[1]
- This anxiety was one factor that led to delaying or withholding of treatments[2]
- Sebetralstat, an oral plasma kallikrein inhibitor, has been approved for the treatment of acute HAE attacks in patients ≥12 years old in the US, UK, and EU[3-5]

The objective of this analysis was to assess the impact of sebetralstat on attack-related anxiety in the pivotal phase 3 KONFIDENT trial

KONFIDENT: NCT05259917; EudraCT: 2021-001226-21. HAE, hereditary angioedema.

1. Fouche AS, et al. *Ann Allergy Asthma Immunol.* 2014;112(4):371-375. 2. Christiansen S, et al. *Ann Allergy Asthma Immunol.* 2024;134(5):570-579. 3. EKTERLY (sebetralstat) tablets, for oral use. US prescribing information. KalVista Pharmaceuticals, Inc; 2025. 4. EKTERLY (sebetralstat). Summary of Product Characteristics. UK prescribing information. KalVista Pharmaceuticals, Inc; 2025. 5. EKTERLY (sebetralstat). Summary of Product Characteristics. EU prescribing information. KalVista Pharmaceuticals, Inc; 2025.

Methods

- Participants reported the baseline attack severity at attack onset using the Patient Global Impression of Severity (PGI-S) scale, ranging from "None" to "Very Severe"
- Participants completed a modified Generalized Anxiety Numeric Rating Scale (GA-NRS) at treatment administration as well as every 0.5 hours during the first 4 hours, every hour from 5 to 12 hours, and every 2 hours from 14 to 24 hours

Attack Characteristics at Treatment Administration

	All attacks (n=264)	Attacks inducing moderate-to-extreme anxiety (n=115/261,[a] 44%)
Baseline attack severity,[b,c] n (%)		
Mild[d]	115 (43.6)	38 (33.0)
Moderate	102 (38.6)	47 (40.9)
Severe/Very severe	45 (17.0)	30 (26.1)

In the absence of injectables, anxiety was correlated with baseline attack severity[e]

[a]Of 261 attacks for which there were GA-NRS ratings at treatment administration. [b]Measured by PGI-S scale at time of treatment administration. [c]Missing: 2 (0.8%) in all attacks. [d]Includes 2 attacks in the all-attacks category and 1 attack in the moderate-to-extreme anxiety category with PGI-S of "None." [e]Assessed using Pearson correlation. n, number of attacks.

Changes in Anxiety over Time

All attacks



Attacks inducing moderate-to-extreme anxiety



On-demand treatment with sebetralstat reduced anxiety, especially in attacks rated as inducing moderate-to-extreme anxiety

SE, standard error.